Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Actovegin in symptomatic diabetic peripheral polyneuropathy
NCT00483730Phase 3Completed
- Sponsor
- Nycomed
- Start
- Dec 2006
- Primary completion
- May 2008
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in peripheral polyneuropathy comparing Actovegin with Placebo (2 arms). Primary endpoints: Total Symptom Score at 160 days and Vibration Perception Threshold at 160 days. Started Dec 2006; status: completed.
02
Drugs
deproteinized calf blood extract
03
Conditions
peripheral polyneuropathy
Beyond the preview
Go deeper on NCT00483730.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00483730.